Inclusion Criteria:

          -  Must have histologically proven loco-regional esophageal or gastroesophageal junction
             adenocarcinoma

          -  Endoscopic ultrasound (EUS) determined node-positive disease with any T-stage or
             T3-T4a with any N stage: Patients with EUS T1N0, T2N0, T4b and any M1 cancer will not
             be included

          -  Must have potentially resectable disease

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Hemoglobin >= 9 g/dL

          -  Absolute neutrophil count >= 1500/mm^3

          -  Platelet count >= 100,000/mm^3

          -  Creatinine < 1.5 upper limit of normal (ULN)

          -  Bilirubin < 1.5 x ULN

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN

          -  Capacity to take oral tablet(s) without difficulty

          -  Participants of child-bearing potential must agree to use highly effective
             contraceptive methods (e.g., hormonal plus barrier method of birth control;
             abstinence) prior to study entry. Should a woman become pregnant or suspect she is
             pregnant while she or her partner is participating in this study, she should inform
             her treating physician immediately

          -  Participant must understand the investigational nature of this study and sign an
             Independent Ethics Committee/Institutional Review Board approved written informed
             consent form prior to receiving any study related procedure

        Exclusion Criteria:

          -  Prior chemotherapy, thoracic radiotherapy or prior surgical resection for an
             esophageal tumor

          -  Participants with known metastatic disease

          -  Any concurrent active malignancy that requires active systemic intervention

          -  Grade 2 or higher peripheral neuropathy

          -  Participants who have had major surgery or field radiation within 4 weeks prior to
             entering the study or those who have not recovered from adverse events due to agents
             administered more than 4 weeks earlier

          -  Received an investigational agent within 4 weeks prior to enrollment

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements

          -  Grade 3 or higher hypersensitivity reaction to oxaliplatin or grade 1-2
             hypersensitivity reaction to oxaliplatin not controlled with premedication

          -  Patient previously treated by TAS 102 or history of allergic reactions attributed to
             compounds of similar composition to TAS 102 or any of its excipients

          -  Hereditary problems of galactose intolerance; e.g., Lapp lactase deficiency or glucose
             galactose malabsorption

          -  Pregnant or nursing female participants

          -  Unwilling or unable to follow protocol requirements

          -  Any condition which in the investigator's opinion deems the participant an unsuitable
             candidate to receive study drug